Tarik Skubal might just be the best pitcher on the planet, hands down. Since July 2023, this lefty has been an absolute machine, putting up a ridiculous 2.47 ERA over 626.1 innings pitched. Dive into the advanced stats and it only gets crazier: a 2.70 xERA, a 2.42 FIP, and a K-BB% of 26.7%, all adding up to a staggering 21.3 fWAR. Every single one of those metrics is tops in baseball over that stretch, and it isn’t even close. He’s got two Cy Youngs (2024 and 2025), a pitcher Triple Crown in 2024, and just broke records with a $32M payday in his final arbitration year this season. Now, at 29 and still in his prime, he’s heading into free agency without the burden of draft pick compensation after his midseason trade from Detroit to LA. This resume arguably makes Skubal the most valuable free agent pitcher of the 2000s, maybe even ever. Gerrit Cole had a better platform year in 2019, sure, but hadn’t been this dominant for multiple years. Yoshinobu Yamamoto was younger but a total unknown in MLB. David Price had a longer track record of good, but less elite, when he signed in 2016. Max Scherzer had a similar production shape but never hit Skubal’s highs. Clayton Kershaw and Stephen Strasburg never even made it to free agency. CC Sabathia might have a case, but pitching has changed so much it’s tough to compare him to anyone from 15+ years ago. It’s no shock then that Skubal is expected to obliterate all free agent pitcher contract records, probably landing somewhere in the $350M to $500M range.
The Alarming Injury History That Could Haunt Any Mega-Deal
Despite all that undeniable talent, the buzz is that the Mets shouldn’t even seriously chase Skubal. And honestly, when you dig into it, you start to see why. There are three huge concerns looming over this guy, but the injury risk is a massive one. Remember when we said his dominance started in July 2023? That wasn’t just some random date. Skubal missed the entire first half of 2023 because he was recovering from flexor tendon surgery, which he had all the way back in August 2022. Then, this past season in 2026, he had *another* procedure, this time to remove loose bodies from his left elbow. To his credit, and his surgeons’, he bounced back super fast. But come on, that’s two operations on his left elbow in the last four years! And don’t forget the Tommy John surgery he underwent in college in 2016. Think about it, the average shelf life for a TJS is typically 5 to 10 years, and Skubal is now at the very back end of that range. This isn’t just a typical pitcher’s injury risk, folks. We’re talking multiple orange, and possibly outright red, warning signs flashing all over the place. Any team considering that kind of money has to be incredibly concerned.
Beyond Skubal: The Age-30 Cliff for Ace Pitchers
It’s not just Skubal’s specific injury history either. There’s a broader trend that should make teams pump the brakes. This class of pitchers, those high-end starters moving into their 30s, historically perform a lot less successfully than you’d expect after they hit that age-30 mark. The data, looking at fWAR accrued after age 30 for pitchers who played between 2000 and 2026, shows that this cohort just doesn’t deliver the same value they did in their younger years. So, you’ve got a guy who is perhaps the best pitcher in baseball, but he’s already had three elbow surgeries, and he’s entering a career phase where even healthy aces tend to decline. The Mets are looking at this, and honestly, every team should be too.
Any club ready to shell out half a billion dollars for Tarik Skubal has to weigh that unparalleled recent dominance against a very real and concerning history of elbow problems and the general age-related performance dip. This is going to be one of the most talked-about free agent signings of the decade, and for good reason. It’s a gamble, no matter how good he’s been.
This article was created with AI assistance and published under Seattle On Tap’s editorial standards. See our Editorial Policy.
Originally reported by Amazin’ Avenue.
Leave a Reply